You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neurofibromatosis 1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)

Recruiting
  • Neurofibromatosis 1
  • Plexiform Neurofibromas
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022

Neurofibromatosis, MPNST Trial run by the National Cancer Institute (NCI) (MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans)

Completed
  • Neurofibromatosis
  • MPNST
  • MRI, FDG-PET/CT scans
  • [18F]-FLT-PET/CT scans
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Recruiting
  • Neurofibromatosis 2
  • Bevacizumab Zirconium Zr-89
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Jan 5, 2023

Neurocognitive Deficit, Mental Health Impairment, Neurofibromatosis 1 Trial in Richmond (OPTIMAL-SSI)

Recruiting
  • Neurocognitive Deficit
  • +2 more
  • OPTIMAL-SSI
  • Richmond, Virginia
    Children's Hospital of Richmond at Virginia Commonwealth Univers
May 16, 2022

Data Collected From Individuals Administered Neurobehavioral

Enrolling by invitation
  • HIV
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 25, 2023

    Measures in Neurofibromatosis 1: Test- Retest

    Suspended
    • Neurofibromatosis Type 1
    • Outcome measures
    • London, United Kingdom
      Guy's Hospital
    Dec 23, 2021

    Frameshift Peptides of Children With NF1

    Completed
    • Neurofibromatosis Type 1
    • Frameshift Array blood sample test
    • Washington, District of Columbia
    • +2 more
    Aug 29, 2022

    Neurofibromatosis 1, Noonan Syndrome, Legius Syndrome Trial run by the National Cancer Institute (NCI) (Waitlist, ACT

    Recruiting
    • Neurofibromatosis 1
    • +4 more
    • Waitlist
    • ACT Intervention
    • Bethesda, Maryland
      National Cancer Institute (NCI)
    Feb 2, 2023

    Cutaneous Neurofibroma Trial in Copenhagen, Gothenburg (TOOsonix System ONE-M)

    Active, not recruiting
    • Cutaneous Neurofibroma
    • TOOsonix System ONE-M
    • Copenhagen, Hovedstaden, Denmark
    • +1 more
    Jun 23, 2022

    Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial in China, Spain, United States (FCN-159)

    Recruiting
    • Neurofibromatosis 1
    • +2 more
    • Los Angeles, California
    • +11 more
    Jul 25, 2022

    Neurofibromatosis 1, NF1, Neurofibromatosis Type 1 Trial in Chicago

    Recruiting
    • Neurofibromatosis 1
    • +2 more
      • Chicago, Illinois
        Ann & Robert H. Lurie Children's Hospital of Chicago
      Mar 11, 2022

      Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

      Active, not recruiting
      • Neurofibromatosis Type 1
      • Minato-ku, Japan
      • +3 more
      Jun 9, 2022

      Hypertension, Neurofibromatosis 1, Blood Pressure Trial in Parkville (Group 1. Standard Home Blood Pressure Measurement, Group

      Not yet recruiting
      • Hypertension
      • +2 more
      • Group 1. Standard Home Blood Pressure Measurement
      • Group 2. Hypnosis script prior to home blood pressure measurement
      • Parkville, Victoria, Australia
        Murdoch Children's Research Institute
      Feb 8, 2022

      Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)

      Active, not recruiting
      • Neurofibromatosis Type 1
      • Rochester, Minnesota
      • +8 more
      Nov 10, 2022

      Neurofibromatosis 1, Chronic Pain Trial in New Haven (iCanCope, iCanCope+Contingency Management)

      Completed
      • Neurofibromatosis 1
      • Chronic Pain
      • iCanCope
      • iCanCope+Contingency Management
      • New Haven, Connecticut
        Frank D Buono, PHD
      Sep 13, 2022

      Neurofibromatosis Type 1 Trial in Washington (CogmedRM, Mobymax)

      Completed
      • Neurofibromatosis Type 1
      • CogmedRM
      • Mobymax
      • Washington, District of Columbia
        Children's National Health System
      Mar 2, 2022

      Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

      Not yet recruiting
      • Hematologic Malignancy
      • +21 more
      • (no location specified)
      Feb 9, 2023

      NF1, Neurofibromatosis, Plexiform Neurofibromas Trial in United States (Cabozantinib)

      Active, not recruiting
      • NF1
      • +2 more
      • Los Angeles, California
      • +11 more
      Jan 13, 2023

      Neurofibroma, Neurofibroma, Plexiform Trial (Cryotherapy)

      Not yet recruiting
      • Neurofibroma
      • Neurofibroma, Plexiform
      • Cryotherapy
      • (no location specified)
      Jan 19, 2022

      Neurofibromatosis 1 Trial in Cincinnati (N-Acetyl cysteine, Placebo)

      Recruiting
      • Neurofibromatosis 1
      • N-Acetyl cysteine
      • Placebo
      • Cincinnati, Ohio
        Cincinnati Children's Hospital Medical Center
      Feb 24, 2022

      NEUROFIBROMATOSIS 1 Trial in Milwaukee (aminolevulinic acid)

      Recruiting
      • NEUROFIBROMATOSIS 1
      • aminolevulinic acid
      • Milwaukee, Wisconsin
        The Medical College of Wisconsin
      Nov 30, 2021

      Cutaneous Neurofibroma, Neurofibromatosis 1 Trial in United States (NFX-179 gel, Vehicle gel)

      Recruiting
      • Cutaneous Neurofibroma
      • Neurofibromatosis 1
      • NFX-179 gel
      • Vehicle gel
      • Little Rock, Arkansas
      • +22 more
      Jan 18, 2023

      FARD (RaDiCo Cohort) (RaDiCo-FARD)

      Recruiting
      • Inherited Epidermolysis Bullosa
      • +8 more
        • Bobigny, France
        • +14 more
        Jul 18, 2023

        Neurofibromatoses, Neurofibromatosis 1, Neurofibromatosis 2 Trial in Boston (Stress and Symptom Management Program 1, Stress and

        Recruiting
        • Neurofibromatoses
        • +3 more
        • Stress and Symptom Management Program 1
        • Stress and Symptom Management Program 2
        • Boston, Massachusetts
          Massachusetts General Hospital
        Sep 7, 2021

        Neurofibromatosis Type 2, Neuroma, Acoustic Trial in Los Angeles (RAD001, everolimus)

        Active, not recruiting
        • Neurofibromatosis Type 2
        • Neuroma, Acoustic
        • RAD001, everolimus
        • Los Angeles, California
          University of California Los Angeles
        Mar 2, 2022